A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
Clinical trial NCT05382325 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05382325
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-16
- Primary completion
- 2026-09-30
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.